Literature DB >> 29502062

[ADS-J1 antagonizes semen-derived enhancer of virus infection-mediated enhancement of transmitted founder HIV-1 and its matched chronic control strain infection].

Hong-Miao Liu1, Ning-Ning Ma, Chun Luo, Shu-Ying Yuan, Fu-Li Liu, Xin-Gang Yao, Chun-Qiong Zhou, Min Zou.   

Abstract

OBJECTIVE: To investigate the effect of semen-derived enhancer of virus infection (SEVI) on the infection of transmitted/founder (TF) HIV-1 and its matched chronic control (CC) viruses and the antagonism of ADS-J1 on SEVI-mediated enhancement of TF and CC virus infection in vitro.
METHODS: PAP248-286 self-assembling into SEVI amyloid fibrils was validated by ThT assay. We generated the virus stocks of TF and CC virus pair. TZM-bl cells were infected with the mixture of SEVI and TF or CC viruses for 72 h. Luciferase activity was used to observe the enhancement of SEVI. SEVI was treated with different concentrations of ADS-J1 and incubated with TF or CC viruses. TZM-bl cells were then infected with the mixture and luciferase activity was detected 72 h after infection to analyze the antagonism of ADS-J1 on the enhancing effect of SEVI. ADS-J1 was also incubated with TF and CC viruses directly and TZM-bl cells were infected for 72 h to evaluate the antiviral effect using luciferase assay. SEVI was treated with ADS-J1 and Zeta potential was determined to explore the antagonistic mechanism of ADS-J1.
RESULTS: ThT assay showed that PAP248-286 was capable of self-assembly into SEVI amyloid fibrils. SEVI significantly accelerated TF and CC viruses infection (P<0.05), and ADS-J1 not only significantly antagonized the enhancement of SEVI (P<0.05) but also directly inhibited the infection of TF and CC viruses (P<0.05). ADS-J1 neutralized the positive charge of SEVI in a dose-dependent manner.
CONCLUSIONS: SEVI promotes the infection of TF and CC strains, and ADS-J1 antagonizes SEVI-mediated enhancement of TF and CC viruses by neutralizing the positive charge of SEVI.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29502062      PMCID: PMC6743876     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  22 in total

1.  Role of donor genital tract HIV-1 diversity in the transmission bottleneck.

Authors:  Debrah I Boeras; Peter T Hraber; Mackenzie Hurlston; Tammy Evans-Strickfaden; Tanmoy Bhattacharya; Elena E Giorgi; Joseph Mulenga; Etienne Karita; Bette T Korber; Susan Allen; Clyde E Hart; Cynthia A Derdeyn; Eric Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection.

Authors:  Tianrong Xun; Wenjuan Li; Jinquan Chen; Fei Yu; Wei Xu; Qian Wang; Ruizhe Yu; Xiaojuan Li; Xuefeng Zhou; Lu Lu; Shibo Jiang; Lin Li; Suiyi Tan; Shuwen Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

3.  ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.

Authors:  Fei Yu; Lu Lu; Qi Liu; Xiaowen Yu; Lili Wang; Elaine He; Peng Zou; Lanying Du; Rogier W Sanders; Shuwen Liu; Shibo Jiang
Journal:  Biochim Biophys Acta       Date:  2014-01-03

4.  Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses.

Authors:  Maral Yolamanova; Christoph Meier; Alexey K Shaytan; Virag Vas; Carlos W Bertoncini; Franziska Arnold; Onofrio Zirafi; Shariq M Usmani; Janis A Müller; Daniel Sauter; Christine Goffinet; David Palesch; Paul Walther; Nadia R Roan; Hartmut Geiger; Oleg Lunov; Thomas Simmet; Jens Bohne; Hubert Schrezenmeier; Klaus Schwarz; Ludger Ständker; Wolf-Georg Forssmann; Xavier Salvatella; Pavel G Khalatur; Alexei R Khokhlov; Tuomas P J Knowles; Tanja Weil; Frank Kirchhoff; Jan Münch
Journal:  Nat Nanotechnol       Date:  2013-01-20       Impact factor: 39.213

5.  Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants.

Authors:  M-R Abrahams; J A Anderson; E E Giorgi; C Seoighe; K Mlisana; L-H Ping; G S Athreya; F K Treurnicht; B F Keele; N Wood; J F Salazar-Gonzalez; T Bhattacharya; H Chu; I Hoffman; S Galvin; C Mapanje; P Kazembe; R Thebus; S Fiscus; W Hide; M S Cohen; S Abdool Karim; B F Haynes; G M Shaw; B H Hahn; B T Korber; R Swanstrom; C Williamson
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

6.  Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.

Authors:  Shilpa S Iyer; Frederic Bibollet-Ruche; Scott Sherrill-Mix; Gerald H Learn; Lindsey Plenderleith; Andrew G Smith; Hannah J Barbian; Ronnie M Russell; Marcos V P Gondim; Catherine Y Bahari; Christiana M Shaw; Yingying Li; Timothy Decker; Barton F Haynes; George M Shaw; Paul M Sharp; Persephone Borrow; Beatrice H Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

7.  Phenotypic properties of transmitted founder HIV-1.

Authors:  Nicholas F Parrish; Feng Gao; Hui Li; Elena E Giorgi; Hannah J Barbian; Erica H Parrish; Lara Zajic; Shilpa S Iyer; Julie M Decker; Amit Kumar; Bhavna Hora; Anna Berg; Fangping Cai; Jennifer Hopper; Thomas N Denny; Haitao Ding; Christina Ochsenbauer; John C Kappes; Rachel P Galimidi; Anthony P West; Pamela J Bjorkman; Craig B Wilen; Robert W Doms; Meagan O'Brien; Nina Bhardwaj; Persephone Borrow; Barton F Haynes; Mark Muldoon; James P Theiler; Bette Korber; George M Shaw; Beatrice H Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-29       Impact factor: 11.205

8.  Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study.

Authors:  Karen Smith-McCune; Joseph C Chen; Ruth M Greenblatt; Uma Shanmugasundaram; Barbara L Shacklett; Joan F Hilton; Brittni Johnson; Juan C Irwin; Linda C Giudice
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

9.  HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck.

Authors:  Jonathan M Carlson; Malinda Schaefer; Daniela C Monaco; Rebecca Batorsky; Daniel T Claiborne; Jessica Prince; Martin J Deymier; Zachary S Ende; Nichole R Klatt; Charles E DeZiel; Tien-Ho Lin; Jian Peng; Aaron M Seese; Roger Shapiro; John Frater; Thumbi Ndung'u; Jianming Tang; Paul Goepfert; Jill Gilmour; Matt A Price; William Kilembe; David Heckerman; Philip J R Goulder; Todd M Allen; Susan Allen; Eric Hunter
Journal:  Science       Date:  2014-07-10       Impact factor: 47.728

10.  Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1.

Authors:  Richard E Haaland; Paulina A Hawkins; Jesus Salazar-Gonzalez; Amber Johnson; Amanda Tichacek; Etienne Karita; Olivier Manigart; Joseph Mulenga; Brandon F Keele; George M Shaw; Beatrice H Hahn; Susan A Allen; Cynthia A Derdeyn; Eric Hunter
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

View more
  1 in total

1.  [PSB0739 inhibits formation of semen-derived amyloid fibril].

Authors:  Yan Lan; Zichao Yang; Han Liu; Hongyan Cheng; Shuwen Liu; Suiyi Tan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.